Tirzepatide: how a dual GIP and GLP-1 agonist actually works
Tirzepatide hits two incretin receptors instead of one, and it does not hit them equally. Here is the pharmacology behind the imbalance, and what the SURPASS and SURMOUNT trials reported.
Research updates
Summaries of published peptide research, framed for laboratory context.
Retatrutide and the TRIUMPH programme: what the trials show
The triple agonist adds a third receptor to the GLP-1 template. Here is what the Phase 2 data reported, what the Phase 3 TRIUMPH trials are showing, and why it remains investigational.
GLP-1 peptides: the complete research guide
What the GLP-1 class actually is, how single, dual, and triple receptor agonists differ, what the trials report, and where each compound stands on approval.
Semaglutide, tirzepatide, and retatrutide: how the three GLP-1s compare
One targets a single receptor, one targets two, one targets three. Here is what the current research says about how they differ, and where each stands on approval.